Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 and Tasquinimod in Bone-only mCRPC
NCT02396368Phase 1Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2015
- Primary completion
- Jul 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of tasquinimod in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Mar 2015; status: withdrawn.
02
Drugs
tasquinimod
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02396368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02396368.